Nevertheless, the presence of tau and Aβ pathology in the olfactory bulbs (OB) of patients with AD, particularly in those with clinically manifested AD (233), underscores the potential benefits of targeting the OB in the treatment of AD. Here, MAPT is linked to Alzheimer disease.